FEATURE ARTICLES
Researchers at the University of Maine may have found a way to do two out of three by developing a new method of producing (S)-3-hydroxy-γ-butyrolactone (HBL) for statins, HIV inhibitors and antibiotics that can lower their production cost with an added benefit of reducing their carbon footprint.
- Roll Call In The Oral GLP-1 Race
- Derisking AI Means First Asking: Who Does It Serve?
- Defining Strong Program Management In CDMO Partnerships
- From Lab to Plant: Managing Operational Environment During Scale-Up
- Sanofi's Digitalization Road Trip Shifts Into High Gear
- Why Pharmaceutical And Medical Device Risks Must Be Analyzed By Their Risk Mechanisms
- The Regulatory Imperative To Improve Environmental And Sustainability Stewardship In Biopharma
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-1214921728-lab-glassware-beaker-vial-test-tube]( "Aggregation In Antibody-Drug Conjugates: Causes And Mitigation")
Aggregation In Antibody-Drug Conjugates: Causes And MitigationDiscover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
Tablet Manufacturing Technologies For Solid Drug Formulation4/2/2025
Compressed tablets are common oral solid dosages that contain the API and various excipients. Learn about the critical steps in selecting manufacturing methods and excipients to achieve the desired therapeutic effects and stability.
-
Manufacturing Challenges With High Concentration Biologics3/18/2024
Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.
-
Ready-To-Use Cartridges: Ensuring Compatibility For GLP-1-Based Drugs8/27/2024
Ready-to-use cartridges for GLP-1 applications offer safe, reliable self-administration. See how they can minimize complexities and better align with the stringent demands of modern manufacturing.
-
Best Practices In Formulation And Lyophilization Development: Proteins, mAbs And ADCs10/16/2024
Discover how advancements in pharmaceutical freeze-drying are reshaping the process through better product understanding, precise process control, and innovations in equipment efficiency.
-
Digital Transformation And Quality By Design For Enhanced Development7/23/2025
Discover how digital transformation and Quality by Design are revolutionizing pharmaceutical development to boost efficiency, enhance compliance, and accelerate innovation across the drug lifecycle.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Expanding CDMO Advanced Therapy Manufacturing Capability With BSL-2LS cGMP Facility
- Depth Filters For The Clarification Of AAV
- Determining The Power Numbers For A Single-Use Mixing System
- AI Unveils Tumor-Immune Landscape In Colorectal Adenocarcinoma
- Modifying The Micro-Environment To Improve Dissolution Rate
NEWSLETTER ARCHIVE
- 10.13.25 -- GMP-Compliant Pharma Manufacturing Equipment: Reactors, Isolators, And More
- 10.13.25 -- Prevent Batch Loss: AI Maintenance And 4x Faster Vial Inspection
- 10.11.25 -- Pharmaceutical Online Best Of September
- 10.10.25 -- Innovative Aseptic And Containment Solutions For Pharmaceutical Manufacturing
- 10.10.25 -- New FDA White Paper Ties Quality To Financial Benefits
INDUSTRY NEWS
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
-
![Dollar Icon from Medical pills-GettyImages-1708867150]( "Oregon Court Upholds Drug Price Transparency Law")
Oregon Court Upholds Drug Price Transparency LawThe law was first enacted in 2018, followed by a lawsuit by Pharmaceutical Research and Manufacturers of America (PhRMA) in 2019, claiming an infringement of free speech for pharmaceutical companies and violation of public property. PhRMA asked the court to bar Oregon from enforcing the law.
-
![Healthcare-GettyImages-1287539899]( "Spray Drying Market Poised To Nearly Double By 2033")
Spray Drying Market Poised To Nearly Double By 2033The growth of the spray drying market is attributed to demand for enhanced stability, bioavailability and solubility of poorly soluble drugs.
-
![Psychedelic Drugs-GettyImages-157676497]( "AbbVie Enters Psychedelic Market With Bretisilocin Acquisition")
AbbVie Enters Psychedelic Market With Bretisilocin AcquisitionBretisilocin is a next-generation psychedelic compound (5-HT2A receptor agonist and 5-HT releaser) designed to exert a shorter duration of psychoactive experience, while retaining an extended therapeutic benefit
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Ypsomed Investing $195M Into Holly Springs, NC Drug Manufacturing Facility10/10/2025
Ypsomed announced plans Oct. 9 to invest $195.4M in Holly Springs for its first North American manufacturing facility. The company will purchase and customize an existing 110,000-square-foot building in the YIELD Holly Springs. This purpose-built manufacturing campus is part of the broader Holly Springs Business Park, located just off N.C. 55. Ypsomed has committed to creating 62 high-quality jobs.
-
Lupin To Build New Drug Manufacturing Facility In Coral Springs, Florida10/10/2025
Global pharmaceutical leader, Lupin, today announced its plans for a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, a significant step in safeguarding the health and safety of Florida families and the nation.
-
Groninger Invests In The Future: Building A state-Of-The-Art Assembly Hall At Its Crailsheim Headquarters10/8/2025
groninger is expanding: A new assembly hall and adjoining office complex are being built, covering more than 75,000 square feet. With an investment volume of over 30 million euros, it marks the largest single investment in the company’s history.
-
TORL Biotherapeutics Secures $96M For ADC Drug Development From UCLA Lab10/7/2025
TORL BioTherapeutics LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, today announced closing of a $96 million Series C financing. Additionally, updated results from the ongoing Phase 1 study of the Company's Claudin 6 (CLDN6) targeted antibody-drug conjugate (ADC) TORL-1-23 in patients with advanced cancer will be presented in poster sessions at the 2025 European Society of Medical Oncology Congress (ESMO 2025) in Berlin, Germany.
-
FDA Announces New ANDA Prioritization Pilot To Support U.S. Generic Drug Manufacturing And Testing10/6/2025
Today, the U.S. Food and Drug Administration (FDA) is announcing a new pilot prioritization program for the review of abbreviated new drug applications (ANDAs) that aims to spur and reward investment in U.S. drug manufacturing and research and development and strengthen the domestic pharmaceutical supply chain by providing faster reviews for generic companies who test and manufacture their products in the U.S.
